Compare Amgen, Inc. (AMGN) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Las Vegas Sands Corp. — how do they compare? Amgen, Inc. trades at $416.7 (market cap $224.14B), while Las Vegas Sands Corp. trades at $45.71 (market cap $29.44B). The key difference: Amgen, Inc. is far larger — about 7.6× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| AMGN | LVS | |
|---|---|---|
Market Cap | $224.14B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $69.49 |
52-Week Low | $271.18 | $44.78 |
Enterprise Value | $267.45B | $41.33B |
Dividend Yield | 2.43% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
LVS trades at $45.68, up 0.48% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $13.02B in 2025, with net income of $1.63B and a 12.59% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains strong profitability metrics, including a 48.52% gross margin and 134.29% ROE. Positive news includes ESG recognitions and community initiatives, supporting a stable operational outlook.
The stock presents a buy opportunity with a consensus price target of $60.75, implying 33% upside, backed by 59% analyst buy ratings. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and sensitivity to macroeconomic factors affecting the gaming and tourism sectors. Institutional sentiment remains positive, but investors should monitor debt management and regional economic conditions for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
